Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription – a multilevel methodological approach by Ohlsson, Henrik & Merlo, Juan
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
Understanding the effects of a decentralized budget on physicians' 
compliance with guidelines for statin prescription – a multilevel 
methodological approach
Henrik Ohlsson*1,2 and Juan Merlo1,2
Address: 1Social Epidemiology & HE, Department of Clinical Sciences in Malmö, Faculty of Medicine, Lund University, Sweden and 2Unit of 
Health and Health Care Epidemiology, Department of Health and Health Care Management, Region Skåne, Sweden
Email: Henrik Ohlsson* - henrik.ohlsson@skane.se; Juan Merlo - juan.merlo@med.lu.se
* Corresponding author    
Abstract
Background: Official guidelines that promote evidence-based and cost-effective prescribing are
of main relevance for obvious reasons. However, to what extent these guidelines are followed and
their conditioning factors at different levels of the health care system are still insufficiently known.
In January 2004, a decentralized drug budget was implemented in the county of Scania, Sweden.
Focusing on lipid-lowering drugs (i.e., statins), we evaluated the effect of this intervention across a
25-month period. We expected that increased local economic responsibility would promote
prescribing of recommended statins.
Methods: We performed two separate multilevel regression analyses; on 110 827 individual
prescriptions issued at 136 publicly-administered health care centres (HCCs) nested within 14
administrative areas (HCAs), and on 72 012 individual prescriptions issued by 115 privately-
administered HCCs. Temporal trends in the prevalence of prescription of recommended statins
were investigated by random slope analysis. Differences (i.e., variance) between HCCs and
between HCAs were expressed by median odds ratio (MOR).
Results: After the implementation of the decentralized drug budget, adherence to guidelines
increased continuously. At the end of the observation period, however, practice variation remained
high. Prescription of recommended statins presented a high degree of clustering within both
publicly (i.e., MORHCC = 2.18 and MORHCA = 1.31 respectively) and privately administered facilities
(MORHCC = 3.47).
Conclusion: A decentralized drug budget seems to promote adherence to guidelines for statin
prescription. However, the high practice differences at the end of the observation period may
reflect inefficient therapeutic traditions, and indicates that rational statin prescription could be
further improved.
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Background
Adherence to prescription guidelines
Prescription guidelines that promote evidence-based and
cost effective prescribing of drugs are of main relevance for
promoting effective and safe pharmacologic treatment as
well as for the efficient use of a limited health care budget.
Therefore, adherence to prescription guidelines has
attracted considerable interest in many countries [1-3],
including Sweden [4-6]. However, it is still insufficiently
known to what extent guidelines from the drug commit-
tees are followed and the factors that at different levels of
the health care condition prescription adherence to rec-
ommended medication [4,7,8].
In a previous study [9], we investigated the role of munic-
ipalities and outpatient Health Care Centres (HCCs) in
understanding adherence to official guidelines on statin
prescription in the county of Scania, Sweden. Using mul-
tilevel regression analysis we developed an epidemiologi-
cal design suitable for monitoring practice variation and
prevalence of adherence to guidelines along time. We
noted that HCCs appeared to be more relevant than
municipalities for understanding physicians' propensity
to prescribe a recommended statin, and that the publica-
tion of the guidelines exerted a positive influence. In other
words, prescription of recommended statins presented
increasing trend and variance between HCCs and munic-
ipalities slightly decreased. However, at the end of the
observation period the prevalence of adherence to guide-
lines was inappropriately low and practice variation
unsuitably high, suggesting that inefficient therapeutic
traditions were still influencing statin prescription. For
this reason, it was suggested that more intensive interven-
tions would be necessary to promote rational statin pre-
scription.
The decentralized pharmaceutical budget
The health services in Sweden are overwhelmingly tax-
financed through county taxes [10]. Even if the Swedish
Health Care System is rather homogenous all over the
country, every of the 20 county councils in Sweden
(Scania is one of the largest) have a high financial auton-
omy for managing health care services within their respec-
tive areas.
In January 2004, the county council of Scania imple-
mented a new system for managing the pharmaceutical
budget. Under the new economic system, responsibility
for the administration of the pharmaceutical budget
passed from the regional Department of Health and
Health Care Management to the 19 administrative Health
Care Areas (HCAs) at five Health Care Districts (HCD) of
the county [11]. See figure 1 for a short explanation of the
structure of the health care system in the County of
Scania. Simultaneously to the decentralized pharmaco-
logical budget, an information campaign was launched.
In this campaign, specially trained pharmacists visited the
HCCs and provided information on current local pre-
scription patterns as a basis for reflection and prescription
improvement. While the new economic system was com-
pulsory, participation in the information campaign was
voluntary.
Aims of the study
In the present study we aimed to monitor and evaluate the
effect of the decentralized pharmacological budget on pre-
scribing behaviour and the role played by the different
organizational levels (HCCs, HCAs and Health Care Dis-
tricts) when it comes to understand physicians' adherence
to prescription guidelines. Statins are an ideal medication
group for this purpose, since they have very homogeneous
indications and similar efficacy [12-14], which in princi-
ple eliminates the possibility of patient mix when com-
paring different practices and administrative areas.
A decentralized drug budget increases economic responsi-
bility among prescribers by relocating control in manage-
ment and decision-making from higher to lower levels of
the health care organization and, thereby, it creates incen-
tives for efficient drug prescription [15]. Therefore, our
hypothesis was that the decentralized pharmacologic
budget and would result in increased use of recom-
mended statins and decreased variance between HCCs
and HCAs throughout the 25-month observation period.
While increased prevalence of adherence is the more
informative parameter of a positive impact of the inter-
vention, only a high prevalence in the area does not nec-
essarily imply better care since it could depend of a few
practices with a very high prevalence. Combining preva-
lence and variance measures we can obtain more com-
plete information.
Due to the hierarchical structure of the data, we applied
multilevel regression analysis (MLRA). MLRA accounts for
and informs about the dependence of the outcome within
organizational levels, and thereby not only produces accu-
rate statistical estimations but also generates information
regarding patterns of variation at different levels – an
aspect of high relevance for investigating therapeutic tra-
ditions [16,17].
Methods
The register of pharmacological agents
We obtained information from the Swedish National Pre-
scription Register [18], administrated by the Swedish Cor-
poration of Pharmacies and based on record of sales.
While the decentralized budget started in January 2004,
the current recommendations for drug prescription were
introduced in March 2004 and so did our observation
period. During the 25-month period between March 2004BMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
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and March 2006 we selected all 110827 prescriptions of
statins issued by public physicians and all 72012 prescrip-
tions issued by private physicians at 136 public and 115
private HCCs in 14 public and 5 private HCAs in Scania.
Statins were defined according to the Anatomical Thera-
peutical Chemical (ATC) classification system code
C10AA [19].
A small percentage (6%; 12 683/195 522) of prescriptions
were excluded since they had unidentified origin, they
were from places outside Scania, or from HCCs with spo-
radic statin prescription (i.e., less than 50 prescriptions)
during the observation period.
Each prescription, regardless of number of drugs, has a
unique serial number in the register. The register data
includes information about the age and gender of the
patient, the health care facility where the prescription was
issued, the brand name and ATC code for both prescribed
and dispensed drugs, and whether the prescription was an
initial or a repeat prescription.
For descriptive purposes we expressed statin utilization as
direct age-standardized number of defined daily doses
(DDD)/1000 inhabitants/day obtained by the Equivalent
Average Rate methodology [20,21].
This study is a part of the LOMAS project (Longitudinal
Multilevel Analysis in Scania) [22] that was reviewed and
approved by the Swedish Regional Ethical Review Board
in Lund.
Individual-level variables
At the individual level, the outcome variable was prescrip-
tion of simvastatin (yes vs. no). Simvastatin (regardless of
brand, but excluding the original brand ZOCORD®) was
the recommended statin in Scania during the whole
observation period. Simvastatin has proved efficacy [12-
14,23] and is the cheapest statin in Sweden. Though a pre-
scription is valid for one year, the reimbursement system
accepts a maximum of three months' supply per dispensa-
tion, so we selected initial prescriptions only in order to
reduce the risk of counting the same prescription more
than once.
The structure of the health care system in the Scania County council Figure 1
The structure of the health care system in the Scania County council.BMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
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Individual age in years was centred on the mean of 67 for
prescriptions issued at public practices, and 66 for those
issued at private practices. Sex  (men vs. women) was
defined by a dummy variable. Time (in months) was a
continuous variable; March 2004 was recoded as 0, April
2004 as 1, and so on to March 2006 that was recorded as
24. Therefore, March 2004 was the intercept value in the
regression analysis.
Area-level variables
The structure of the health Care System at the county of Scania
The Region of Scania is situated on the southern part of
the Scandinavian Peninsula. The county is geographical
divided into 33 municipalities and its area covers less than
3% of Sweden's total area. The population of about 1.2
million represents, however, 13% of Sweden's total popu-
lation. At the time of this study the health care system at
the county of Scania was organized into five health care
districts (northwest, northeast, southwest, southeast, and
central). These five health care districts managed 19
administrative HCAs which, in turn, controlled 251 HCCs
(Figure 1). Of those HCCs, 136 were public administered
primary health care centres and hospital outpatient care
clinics, and 115 were private primary HCCs assisted by
private general practitioners (GPs) and other private spe-
cialists. Only five of the 19 HCAs managed private HCCs.
The remaining 14 HCAs managed only public HCCs; nine
HCAs managed only outpatient clinics at large public hos-
pitals while five administered primary health care centres.
Participation in the information campaign
Simultaneously to the introduction of the decentralized
budget, an information campaign for supporting appropri-
ate prescription at the HCCs was carried out through the
entire observation period. Participation in this campaign
was voluntary. Since the campaign could influence pre-
scription patterns independently of any possible effect of
the decentralized budget, we included a variable indicat-
ing whether the HCC participated in the information
campaign or not.
Budget decentralization at the HCA level and HCCs with own budget 
administration
In the new compulsory system of decentralized pharma-
ceutical budget, the responsibility for the administration
of the pharmaceutical budget was transferred from the
regional Department of Health and Health Care Manage-
ment to every of the 19 administrative HCAs. However,
nine of the 14 publicly-administered HCAs decided to
implement a more intense decentralization by transfer-
ring the budget responsibility to their HCCs. Since this cir-
cumstance could influence prescription patterns, such
HCCs were identified by a dummy variable. In the analy-
ses, HCCs without their own budget management were
used as reference in the comparisons.
Percentage of prescriptions from specialist physician at the HCC level
Since proximity to specialized care and the particular
knowledge that it conveys might influence adherence with
prescription guidelines, we also identified those HCCs
which employed specialist physicians other than GPs. In
the analyses, HCCs employing GPs alone were used as ref-
erence in the comparisons.
Multilevel logistic regression models
We used multilevel logistic regression analysis to estimate the
probability of prescribing a recommended statin, while
accounting for the hierarchical structure of the data (i.e.,
patients nested within HCCs nested within HCAs) repre-
sented in figure 1[16,17].
Since physicians working in private practices may be less
receptive to the policies of the county council than those
working in public facilities, and because this might mod-
ify the effect of the decentralized budget, we performed
our analyses separately for physicians under public or pri-
vate administration
Public HCCs and HCAs were included in the analysis as
random terms. However, because there were only five
health care districts, which is a low number for including
health care districts as a random term, they were included
as a dummy variable (i.e., fixed effects), using the south-
west district as reference in the comparisons. Since there
was only one private HCA in each health care district, in
the multilevel analysis of privately administered health
care the only random term was HCC.
We developed three consecutive models. Model A
included the area (i.e., HCA and HCC) random parame-
ters together with time. The intention of this model was to
investigate temporal trends of prescription of recom-
mended statins throughout our observation period.
Model B included the individual covariates age and sex.
Finally, model C added the area-level variables; health
care districts, information campaign, presence of special-
ist physicians other than GPs, and HCC with own budget
responsibility. In this way we could investigate whether
these contextual characteristics explained residual varia-
tion at the HCC and HCA levels.
In the fixed-effects part of the multilevel analysis, we cal-
culated odds ratios (OR) and their 95% confidence inter-
vals (95% CI) from the regression coefficients and their
standard errors.
In the random-effects part of the multilevel analysis, we
obtained the variance (SE) at the HCC and HCA levels. We
calculated the proportional change in variance (PCV)
between two consecutive models [24]. We also allowed
the regression coefficients of the variables time and sex toBMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
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be random at the HCC level (i.e. random slope analysis)
in order to investigate whether these individual-level asso-
ciations varied between different HCCs. In the presence of
slope variance, the HCC variance becomes a function of
the individual variables. We calculated the variance func-
tion as described elsewhere [25].
Theoretically the concept of intraclass correlation (i.e., the
percentage of the total variance that is at the area level) is
an intuitive measure of therapeutic traditions [9,26,27].
However, in multilevel logistic regression models, the fact
that the variances at the area and at the individual levels
are measured on different scales makes it difficult to inter-
pret the intraclass correlation. Therefore, we calculated the
median odds ratio (MOR) [28,29]. The MOR translates
the variance into the widely used OR scale, and can
thereby be directly compared with the ORs of individual
or area variables. In very simple terms, the MOR could be
interpreted as how much a physician's probability of pre-
scribing a recommended statin would (in median)
increase if this physician moved to a HCC/HCA with
higher adherence to guidelines. A MOR of 1 indicates that
there are not differences between HCCs/HCAs in the
probability of prescribing a recommended statin. The
larger the differences between HCCs (or HCAs) are, the
larger the MOR will be.
Even if the overall OR for the association between an area
(i.e., HCC or HCA) variable and the outcome is conclu-
sively higher or lower than one, the distribution of OR for
pairwise comparison between exposed and unexposed
areas could contain a considerable percentage of ORs of
opposed direction. Therefore, we calculated the percent-
age of ORs of opposed direction as complementary infor-
mation to the overall OR of each area-level variable. This
index considers the area residual variance in the calcula-
tion of the ORs of the area level variables, and indicates
the extent to which the area variable under study is of
importance as compared with residual area variations. If
the index is 50% the association has no relevance. Details
of the formulas and an extended explanation of the statis-
tical analysis can be found elsewhere [30]. An Excel
spreadsheet with formulas is available on request.
Ranking of outpatient health care centres and 
administrative health care areas
Following previous recommendations for comparing per-
formance between different health care units [31], we
ranked HCCs and HCAs according their posterior means
(also known as "shrunken residuals") obtained from the
multilevel regression analyses. Each residual corresponds
with the OR of adherence with guidelines (logarithmic
scale) of the unit, with the whole county as reference in
the comparisons.
Parameters were estimated by MCMC methods [32] and
the goodness of fit was evaluated using the deviance infor-
mation criteria (DIC). We used the MLwiN 2.02 software
developed by Goldstein's research group [25].
Results
The age-standardized utilization of statins in the whole
county increased from 131 DDD/1000 inhabitants/day in
2004 to 177 in 2006, and a similar increasing trend was
observed in all health care districts. Throughout the whole
observation period, prescription of statins was highest in
the northwest district and lowest in the central district
(Table 1).
Table 1 shows that the mean age of the patients receiving
a statin prescription was 67 years in the public sector and
66 years in the private. Overall, men were prescribed stat-
ins more often than women. More statin prescriptions
were issued from public HCCs than from private HCCs.
Of all the statin prescriptions issued at public HCCs, 82%
originated from a HCC participating in the information
campaign, but this figure was only 22% for private HCCs,
and varied greatly between districts, being lowest in the
southwest district. More statins were prescribed by HCCs
composed of GPs alone than by HCCs including other
specialists. Of the statin prescriptions issued at public
HCCs, 71% originated from HCCs that managed their
own pharmacologic budget.
Overall, the prevalence of guideline adherence was 62%
in the public sector and 50% in the private, with a clear
increasing trend during the whole study period. In the first
month, 48% of the public and 39% of the private HCCs
prescribed recommended statins, and this percentage
increased to 74% in the public and 62% in the private sec-
tor by the end of the study period. These trends were sim-
ilar in all five health care districts, but adherence was
always lowest in the southwest district, and highest in the
northeast and southeast districts (Figure 2).
In model A (see Table 2), the MORHCA-HCC in the public
sector was 2.28 indicating that a physician's median prob-
ability of prescribing a recommended statin would
approximately double if this physician moved to an HCC
in an HCA with greater adherence to guidelines. However,
when decomposing the MOR in specific levels, the pro-
pensity of prescribing recommended statins presented a
higher degree of clustering at the HCC level than at the
HCA level (MORHCC = 2.18 vs. MORHCA = 1.31). The
MORHCC in the private sector was 3.47, indicating an even
stronger clustering among private HCCs.
As illustrated in Figure 2, there was an increasing temporal
trend in prescription of recommended statins. However,
this trend differed between HCCs, and the time variableB
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Table 1: Characteristics of the initial prescriptions of statins issued in Scania, Sweden, between March 2004 and March 2006, by Health Care District and specifying prescription of 
simvastatin (i.e., recommended drug).
Whole Scania North-West North-East Central South-West South-East
All Simvastatin All Simvastatin All Simvastatin All Simvastatin All Simvastatin All Simvastatin
Number of prescriptions (Public HCCs) 110,827 68,372 (62%) 27,562 17,138 (62%) 19,145 12,978 (68%) 27,509 15,932 (58%) 28,373 16,264 (57%) 8,328 6,060 (74%)
Number of prescriptions (Private HCCs) 72,082 36,256 (50%) 20,270 9,958 (53%) 7,801 4,656 (64%) 7,922 4,342 (58%) 34,024 13,224 (42%) 7,272 4,076 (60%)
Men Public/private 56/55 55/55 53/55 53/55 55/55 55/56 58/52 57/52 56/55 56/55 57/55 57/54
Mean age in years (Public/private) 67/66 67/65 67/67 67/66 68/68 67/68 67/65 67/65 66/66 66/66 68/67 68/67
Number of HCAs (Public/private) 14/5 3/1 3/1 3/1 3/1 2/1
Number of HCCs (Public/private) 136/115 29/28 25/13 36/18 39/41 7/15
Percentage of prescriptions from HCCs that participated in information campaign 
(Public/private)
82/22 82/28 98/24 97/27 97/80 97/80 100/47 100/50 33/0 31/0 100/34 100/36
Percentage of prescriptions from HCCs with own budget administration (Public) 71 71 83 81 87 86 91 89 38 42 35 36
Percentage of prescriptions from specialist physician (Public/private) 34/37 37/34 29/38 32/33 32/4 35/2 35/41 37/43 38/48 42/46 35/15 36/20
DDD/inhabitants/day for statins
DDD/inhabitants/day, 2004 131 153 127 110 132 129
DDD/inhabitants/day, 2005 152 180 147 126 152 154
DDD/inhabitants/day, 2006 177 207 171 147 178 186
HCC = outpatient health care centre.BMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
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presented a significant slope variation between HCCs evi-
denced by the plot of the predicted values in Figure 3.
Because of this slope variance, the MORHCC became a
function of time indicating that even if the MORHCC
decreased throughout the study period, the final variation
was still high (MORHCC = 1.86 in the public sector and
2.73 in the private).
We did not observe any significant slope variation of the
time variable at the HCA level.
The analysis of the PCV in Table 2 indicates that 50% of
the differences between HCAs were explained by the indi-
vidual and contextual characteristics included in model C.
In relation to variance between HCCs, this percentage was
only 8% in the public sector and 0% in the private. The
DIC diagnosis suggested that model C represent an
improvement over model B in goodness of fit for the pub-
lic sector, but not for the private.
The ranking of the HCCs and HCAs regarding the preva-
lence of prescription of recommended statins in each area
relative to the overall prevalence in the county at the
beginning of the study period is presented in Figure 4
both before (model A) and after (model C) making
adjustments. The differences between HCAs disappeared
after adjustment, but although many HCCs changed posi-
tion in the ranking, the HCC dispersion around the mean
was not reduced after adjustments.
Overall, men had higher use of statins (Table 1) but lower
probability than women of being prescribed a recom-
mended statin (Table 2). The existence of slope variation,
however, indicated that this pattern of association was not
constant in all HCCs.
Table 2 shows that the probability of prescribing recom-
mended statins was not conditioned by participating in
the information campaign. Also, our results suggest that
even if adherence to guidelines clearly improved after the
implementation of the decentralized budget, this
improvement was not more intense among HCCs with
own budget administration. Actually – even if the results
were not conclusive at the 95% level – comparing to HCC
without own budget administration those with own eco-
nomical responsibility presented a lower, rather than
higher, probability of adherence with guidelines, OR =
0.82 (95%CI: 0.68–1.06),
Among the public HCCs, prescriptions of recommended
statins were more frequently issued at HCCs with special-
ist physicians other than GPs, but no such association was
observed for private HCCs. Compared with the southwest
district, all other districts presented a higher probability of
prescribing recommended statins for both public and pri-
vate HCCs, except public HCCs in the central district.
DiscussionIn this study we evaluated the effect of a decen-
tralized pharmaceutical budget intended to promote
Percentage of recommended statins among initial statin prescription in the health care districts of the county of Scania, public  health care centres (right) and private health care centres (left) Figure 2
Percentage of recommended statins among initial statin prescription in the health care districts of the county of Scania, public 
health care centres (right) and private health care centres (left).B
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Table 2: Multi-level logistic regression analysis of adherence to statin prescription guidelines in the county of Scania, Sweden
Model A Model B Model C
Public Private Public Private Public Private
Fixed effects OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Time 1.05 (1.04–1.05) 1.06 (1.05–1.07) 1.05 (1.04–1.05) 1.06 (1.05–1.07) 1.05 (1.04–1.05) 1.05 (1.04–1.07)
Time^2 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Sex (women vs men) 0.93 (0.87–0.98) 0.92 (0.84–1.01) 0.93 (0.88–0.99) 0.92 (0.85–0.99)
Age (one year increase) 1.000 (1.000–1.000) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Information campaign (Yes vs No) 1.11 (0.90–1.39) 1.46 (0.73–2.34)
% opposed ORs 46% 42%
Specialist physician vs GP 1.41 (1.18–2.01) 0.97 (0.66–1.31)
% opposed ORs 38% 49%
HCC with own budget administration (yes vs No) 0.82 (0.68–1.06)
% opposed ORs 43%
North-West health care district – – 1.37 (1.01–1.93) 1.66 (1.09–2.50)
% opposed ORs 39% 39%
North-East health care district – – 1.39 (0.84–2.04) 1.78 (1.04–3.89)
% opposed ORs – – 39% 38%
South-West health care district – – Reference Reference
South-East health care district – – 2.03 (1.08–3.92) 1.46 (0.84–1.99)
% opposed ORs – – 27% 42%
Central health care district – – 0.85 (0.47–1.15) 1.53 (1.10–2.73)
% opposed ORs – – 45% 41%
Random effects Variance (95% CI) Variance (95% CI) Variance (95% CI) Variance (95% CI) Variance (95% CI) Variance (95% CI) PCV
HCA (intercept) 0.08 (0.01 – 0.38) 0.15 (0.04 – 0.42) 0.04 (0.00–0.17) 50%
MORHCA 1.31 (1.11 – 1.80) 1.44 (1.22 – 1.87) 1.21 (1.04 – 1.49)
HCC (intercept) 0.67 (0.51 – 0.89) 1.70 (1.28 – 2.32) 0.62 (0.46 – 0.84) 1.80 (1.34 – 2.44) 0.62 (0.47 – 0.82) 1.71 (1.26 – 2.34) 8% (Pu)
MORHCC 2,18 (1.98 – 2.46) 3.47 (2.94 – 4.28) 2,12 (1.92 – 2.39) 3.60 (3.01 – 4.43) 2.12 (1.92 – 2.37) 3.48 (2.92 – 4.31) 0% (Pr)
OHC and HCA (intercept) 0.75 0.77 0.66 12%
MORHCA-HCC 2.28 2.31 2.17
Time (slope) 0.000 (0.000 – 0.001) 0.001 (0.001 – 0.002) 0.000 (0.000 – 0.001) 0.001 (0.001 – 0.002) 0.000 (0.000 – 0.001) 0.001 (0.001 – 0.002)
Sex (slope) – 0.063 (0.043 – 0.093) 0.149 (0.103 – 0.214) 0.063 (0.043 – 0.094) 0.147 (0.102 – 0.214)
Deviance information criteria (DIC) 136 649.6 87 811.1 136 114.6 87 421.9 136 113.9 87 422.4
HCC = outpatient health care centre. MOR = median odds ratio. OR = odds ratio.
95% CI = 95% credible interval. SE = standard error.
PCV = proportional change in variance (PCV) in model C using model A as referenceBMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
Page 9 of 13
(page number not for citation purposes)
adherence with prescription guidelines. According to our
results, this intervention appeared to considerably
improve adherence to guidelines for statin prescription
and, promoted efficient pharmacological treatment.
We performed separate analyses for publicly and privately
administrated HCCs, since we believed that the adminis-
trative background could modify the effect of these inter-
ventions. However, even though guideline compliance
was systematically lower among private facilities, compli-
ance in both the public and the private sector increased
progressively from the implementation of the decentral-
ized budget through the observation period.
Since our study is observational, several bias and con-
founding factors need to be considered. While face-to-face
visits such as those performed during the intervention
campaign have a documented effect on prescription pat-
terns [33], in our analysis participation in the information
campaign was not associated to higher adherence with
guidelines. Given that participation in this campaign was
free, it is probable that other reasons apart from the infor-
mation campaign itself confound the observed associa-
tion. For example, HCCs with a very low adherence to
guidelines at the start of the intervention may be espe-
cially prone to participate in order to improve their pre-
scription patterns. This effort would have only raised
adherence to the same level as rest of the HCCs. Due to
selection biases interpretation of the effect of the informa-
tion campaign is limited.
Evaluation of the decentralized budget was less affected
by bias since the adoption of the new budget system was
obligatory and embraced all the prescribers in the county.
Nevertheless, it cannot be ruled out that other external
influence besides the decentralized budget could provide
an alternative explanation of our results. Also, as we
shown in our previous article [9], adherence with guide-
lines was slightly increasing before the implementation of
the decentralized budget. Nevertheless, it is reasonable to
believe that the intense trend of increasing prescription of
simvastatin occurring after the implementation of the
budget actually reflects the new economic responsibility
of the prescribers. Several studies suggest that payment
method affects physicians' prescription behaviour
[2,33,34]. Moreover, even if guideline dissemination
alone has a less important effect on prescribing patterns
[9,33,34], it has proved to be effective as part of a multi-
faceted intervention and as a predisposing foundation for
other strategies.
Observational studies are often the only option for inves-
tigating questions that for reasons of feasibility, costs, or
ethics cannot be analysed by randomized trials [35,36]. In
our observational study we used multilevel regression
analysis, which not only produces more correct statistical
analysis (i.e., it accounts for residual correlation within
areas) but also informs about the role that different health
care levels play in understanding drug prescription and
utilization [16,17].
Predicted probabilities for prescribing recommended statins at public (left) and private (right) health care centres in Scania Figure 3
Predicted probabilities for prescribing recommended statins at public (left) and private (right) health care centres in Scania.BMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
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Our results suggest that adherence to guidelines seemed to
be conditioned by contextual factors, especially at the
HCC levels. Based on the MOR measure, we observed that
physicians from the same HCC and from the same HCA
exhibited a similar propensity to prescribe simvastatin.
This clustering of prescription behaviour was greater at the
HCC than at the HCA level, which suggest that interven-
tions directed at the HCC level would in principle be more
effective than those directed at the HCA level. Also, private
HCCs had both greater clustering of prescription behav-
iour and lower adherence to guidelines, suggesting that
interventions directed at private HCCs could be appropri-
ate.
In a previous multilevel analysis [9] we investigated HCCs
nested within municipalities rather than within HCAs as
in the present study. However, since HCAs are responsible
for the management of the new decentralized budget, we
did not consider the municipality as a relevant level in this
investigation, and a sensitivity analysis (data not shown)
including the municipality level confirmed our assump-
tion. In the present study we did not have access to infor-
mation at the physician level, but two previous studies
have shown that variations at the physician level
accounted for about 50% of variations at the HCC level
[37,38].
The variation between public HCAs was very low and
could partly be explained by contextual characteristics
such as health care district, participation in the informa-
tion campaign, the presence of specialist physicians other
than GPs, and degree of decentralization. Contrarily, the
variation between both public and private HCCs was very
high and remained unexplained throughout the whole
observation period (i.e., model C in Table 2). Practice var-
iation between HCCs is a common phenomenon that
does not necessarily need be inappropriate, but rather
may reveal different strategies for confronting a specific
therapeutic problem. Practice variation might reflect med-
ical uncertainty resulting from differences in information
and knowledge. However, when the same pharmacologi-
cal therapy is available as different brands at different
prices and the prescriber selects the more costly, there are
reasons to question the suitability of the observed practice
variation [26,27,39-43]. In this context and since all stat-
ins have the same indication and only marginal differ-
ences in efficacy, there are no solid reasons for justifying
the prescription of expensive brands in general and for
some patients rather than others in particular [12-14].
The process of prescription includes a number of phases
(identification of the health problem, decision to pre-
scribe, choice of medication, decision to cease using a spe-
cific therapy) and could be influenced at different levels
(e.g. at the level of the patient, prescriber, HCC, HCA, or
health care district). However, few studies have aimed to
understand the relative importance of these different lev-
els [7,26,27,37,44]. Moreover, even if adherence with
guidelines in general is a well-developed research topic [1-
3], as far we know only to investigations have been
focused on adherence to guidelines of statin prescription,
[45,46] and only our current and previous work has
applied multilevel regression analyses [9]. The present
investigation provides valuable and original information
Differences (i.e. residuals) between health care centres  obtained from the model including random parameters  together with time (unfilled circles) and the model also  including age, sex, health care districts, information campaign,  presence of specialist physician other than general practition- ers, and degree of decentralization (filled circles) Figure 4
Differences (i.e. residuals) between health care centres 
obtained from the model including random parameters 
together with time (unfilled circles) and the model also 
including age, sex, health care districts, information campaign, 
presence of specialist physician other than general practition-
ers, and degree of decentralization (filled circles). Public 
administrative health care areas (top), public health care cen-
tres (middle), and private health care centres (bottom).BMC Health Services Research 2007, 7:68 http://www.biomedcentral.com/1472-6963/7/68
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that could be of relevance for planning and evaluating
interventions aimed to promote efficient and evidence-
based prescription.
Because of similar indications and efficacy, statins are an
ideal medication group for investigating prescribing
behaviour. For this reason, there is no rationale for con-
sidering patient characteristics as confounding factors
when investigating practice variation. Rather, the value of
including individual variables resides in the understand-
ing of the factors that condition adherence to prescribing
guidelines. In the present investigation we only consid-
ered basic individual variables such as age and gender. An
extended study of determinants of adherence to guide-
lines may also require the investigation of the influence of
socioeconomic differences of the patients on the process
of prescribing as well as applying qualitative research
methodology [47].
According to the prescription guidelines in the county of
Scania there is one patient related condition in which a
non-recommended statin has a preferential indication
[14]. In fact, when simvastatin does not reach sufficient
effect, a change to atorvastatin 80 mg is officially recom-
mended. However, a complementary analysis indicates
that atorvastatin 80 mg was only 0.5% of all the statin pre-
scriptions, and including this substance in the category of
recommended statin had no influence on the results.
In a previous study of ours performed in the county of
Scania, the basal level of adherence with recommended
statins was much lower than in the present investigation.
The main reason for this difference is that in the previous
study period, guidelines were very strict, including only
Pravachol and Simvastatin GEA rather than Simvastatin as
in the present investigation. Certainly, the existence of
plain guidelines facilitates adherence, but it does not
influence the conclusions of the present investigation.
Our empirical analysis found that men were prescribed
more statins than women, but women had a slightly
higher probability than men of being prescribed the
cheaper, recommended, statins. Men have a higher preva-
lence of ischemic heart disease and they are therefore
expected to be more represented among statin users. On
the other hand, the gender differences in the prescription
of simvastatin did not seem rational. It is possible that
qualitative analyses would give more information on the
reasons for this prescribing behaviour.
It is known that some non-recommended statins like
rosuvastatin have been the subject of safety concerns [48-
50], which may have promoted prescription of simvasta-
tin beyond the influence of the guidelines. However, if
this is true, this external influence simultaneously affected
all the HCCs and HCAs and therefore should have had
less relation to variance between HCCs and HCAs.
Multilevel regression analyses are a very suitable method-
ology for studying practice variation, and are being suc-
cessfully employed in an increasing number of studies in
the field [7,9,26,27,37,44,51]. They are a useful epidemi-
ological tool for investigating and quantifying medical
practice variation, and for evaluating and planning inter-
ventions.
Conclusion
In conclusion, the decentralized pharmaceutical budget
seems to considerably influence prescription behaviour
and increase adherence to guidelines for statin prescrip-
tion. Though, at the end of the observation period, varia-
tion between HCCs was still high, especially among
private HCCs. These remaining disparities may reflect
inefficient therapeutic traditions, and suggest that more
intensive interventions may be necessary to promote
adherence to prescription guidelines [52]. Obviously, a
decentralized pharmaceutical budget [11,15] transfers
power in management and decision-making from higher
to lower levels of the health care organization, which in
turn increases economic responsibility among prescribers
and creates incentives for efficient drug prescription.
Therefore, as a natural consequence, adherence to the
drug committee's recommendations increases.
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